Please assess the completion status of the following clinical trial:

Trial Title: Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Man or woman \> 18 years old~* Patient with wAMD previously treated with ranibizumab (for less than 12 months before initiation of Aflibercept)~* Refractory to ranibizumab (defined by persistent fluid despite a treatment conducted according to the HAS French recommendations with at least 3 loading doses injections)~* Patient who switched to aflibercept (Eylea) between 1st of January 2014 and 30th June 2015~* Written informed consent given~Exclusion Criteria:~* Patient who do not meet the local indication criteria for aflibercept treatment. Contraindications listed in the local SmPC (Summary of Product Characteristics) have to be considered~* Recurrent patients with wAMD previously treated with ranibizumab and switched to aflibercept because of a high recurrence rate (recurrent patients described by Yonegawa et al.in AJO (American Journal of Ophthalmology )2013= exudation suppressed but high rate of injections)~* Patient who have been previously treated by any macular laser Visudyne/PD (Photodynamic therapy)~* Patient with a Visual Acuity (VA) \<1/10~* Patient with Fibrosis involving Macula~* Patient with atrophic AMD~* Patient with any other retinal disease as myopia, diabetic retinopathy, diabetic macular oedema,chorioretinal anastomosis (CRA),, angioid streaks~* Patients taking part in an interventional study at the time of enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): According to the recommendations of the Summary of Products Characteristics (SmPC) Administration by intravitreal injection

Based on this trial design, predict the completion outcome and termination type (if applicable).